KR20210141936A - 셀리넥서의 공결정 형태 - Google Patents

셀리넥서의 공결정 형태 Download PDF

Info

Publication number
KR20210141936A
KR20210141936A KR1020217028384A KR20217028384A KR20210141936A KR 20210141936 A KR20210141936 A KR 20210141936A KR 1020217028384 A KR1020217028384 A KR 1020217028384A KR 20217028384 A KR20217028384 A KR 20217028384A KR 20210141936 A KR20210141936 A KR 20210141936A
Authority
KR
South Korea
Prior art keywords
selinexer
succinic acid
crystal
vanillin
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217028384A
Other languages
English (en)
Korean (ko)
Inventor
클립톤 해밀턴
Original Assignee
존슨 맛쎄이 퍼블릭 리미티드 컴파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 존슨 맛쎄이 퍼블릭 리미티드 컴파니 filed Critical 존슨 맛쎄이 퍼블릭 리미티드 컴파니
Publication of KR20210141936A publication Critical patent/KR20210141936A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C07C47/58—Vanillin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217028384A 2019-03-20 2020-03-19 셀리넥서의 공결정 형태 Withdrawn KR20210141936A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962821203P 2019-03-20 2019-03-20
US62/821,203 2019-03-20
PCT/US2020/023530 WO2020191140A1 (en) 2019-03-20 2020-03-19 Co-crystal forms of selinexor

Publications (1)

Publication Number Publication Date
KR20210141936A true KR20210141936A (ko) 2021-11-23

Family

ID=70293085

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217028384A Withdrawn KR20210141936A (ko) 2019-03-20 2020-03-19 셀리넥서의 공결정 형태

Country Status (8)

Country Link
US (1) US12559478B2 (https=)
EP (1) EP3941588A1 (https=)
JP (2) JP2022524741A (https=)
KR (1) KR20210141936A (https=)
CN (1) CN113423468A (https=)
BR (1) BR112021016762A2 (https=)
CA (1) CA3130107A1 (https=)
WO (1) WO2020191140A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021016762A2 (pt) 2019-03-20 2021-10-19 Johnson Matthey Public Limited Company Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104230936A (zh) * 2009-12-03 2014-12-24 阿斯利康(瑞典)有限公司 三唑并[4,5-d]嘧啶血小板聚集抑制剂的共晶体
EP4234545A3 (en) 2011-07-29 2023-09-06 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
US9808450B2 (en) * 2013-03-26 2017-11-07 Celgene Corporation Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
US20180230140A1 (en) * 2014-06-30 2018-08-16 Basf Se Multicomponent crystals of dasatinib with menthol or vanillin
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
EP3565813A1 (en) * 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
CN107089946B (zh) * 2017-05-05 2020-04-03 浙江科技学院 一种诺氟沙星与香兰素共晶及其制备方法
BR112021016762A2 (pt) 2019-03-20 2021-10-19 Johnson Matthey Public Limited Company Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor

Also Published As

Publication number Publication date
BR112021016762A2 (pt) 2021-10-19
US20210395232A1 (en) 2021-12-23
CA3130107A1 (en) 2020-09-24
JP2025134935A (ja) 2025-09-17
JP2022524741A (ja) 2022-05-10
CN113423468A (zh) 2021-09-21
EP3941588A1 (en) 2022-01-26
US12559478B2 (en) 2026-02-24
WO2020191140A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
CN110088088B (zh) {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
JP7561240B2 (ja) ピリジノイルピペリジン５－ｈｔ１ｆアゴニストに関する組成物および方法
KR20160121544A (ko) N-｛4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐｝-n''-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법
TWI675839B (zh) 一種ｊａｋ激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法
TR201807316T4 (tr) Bir faktör XIa inhibitörünün kristalli formları.
CN102791719A (zh) 二胺衍生物的晶体及其制备方法
CN107427503A (zh) 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
WO2014082354A1 (zh) 西达本胺的晶型及其制备方法与应用
JP2025131661A (ja) ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
JP2025134935A (ja) セリネクソールの共結晶形態
WO2014193866A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihydroimidazo[4,5- d]fy rrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
KR102858471B1 (ko) Lta4h 저해제의 결정질 형태
EA039764B1 (ru) Соль n-(2,6-диэтилфенил)-8-({4-[4-(диметиламино)пиперидин-1-ил]-2-метоксифенил}амино)-1-метил-4,5-дигидро-1h-пиразоло[4,3-h]хиназолин-3-карбоксамида, ее получение и препараты, которые ее содержат
JP2022540466A (ja) 非晶質ウムブラリシブモノトシレート
KR101285050B1 (ko) 결정형 1Ｈ-이미다조[4,5-ｂ]피리딘-5-아민,7-[5-[(시클로헥실메틸아미노)-메틸]-1Ｈ-인돌-2-일]-2-메틸, 설페이트 (1:1), 삼수화물 및 이의 약학적 용도
WO2023222122A1 (en) Solid forms of a compound for treating or preventing hyperuricemia or gout
WO2019246479A1 (en) Form of ponatinib
EP3004104A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
WO2011077252A2 (en) Metaxalone cocrystals
HK40115548A (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
JP2008540449A (ja) （２ｅ，４ｓ）−４−［（ｎ−｛［（２ｒ）−１−イソプロピルピペリジン−２−イル］−カルボニル｝−３−メチル−ｌ−バリル）（メチル）アミノ］−２，５−ジメチルヘキサ−２−エン酸の非溶媒和およびホストゲスト溶媒和結晶フォーム、およびそれらの医薬的使用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000